Aim: We tested a selected series of patients with single urothelial high-grade pT1 stage (pT1 HG) or urothelial carcinoma in situ (CIS) with a set of immunohistochemical markers to elaborate a risk score for progression. Patients and Methods: We retrospectively reviewed all first diagnoses of single, <3 cm, urothelial papillary carcinoma pT1 HG or isolated CIS between 2006 and 2009. Galectin-3, CD44, Ecadherin, CD138, p16, survivin, HYAL-1, and topoisomerase- II α were used. A grading score 0 or 1 for each immunohistochemical staining was assigned to obtain a total score for assessing progression. The median “progression score” was selected as cut-off value for statistical analysis. Overall, 23 patients (19 pT1 HG and 4 CIS) were included in the study. Results: After a median follow-up of 21 months (range, 12 to 34 mo), 9 patients (39.1%) showed disease recurrence whereas 4 patients (17.4%) showed tumor progression. Topoisomerase-II α, p16, survivin, galectin-3, and CD138 were significantly associated with progression. Progression score ranged from 0 (best prognosis) to 7 (worst prognosis). Using a score ≥5 as a threshold, specificity was 78.9%, sensitivity 100%, positive predictive value 50%, and negative predictive value 100%. ROC area (a 95% confidence interval, 0.807-1.000; p<0.001). Conclusion: This immunohistochemistry-based progression score using a threshold ≥5, might help the clinician to focus on patients with HG pT1 or extended CIS at high risk for disease progression. These patients might benefit from a more intensive follow-up program or early cystectomy.

A PROPOSED SCORE FOR ASSESSING PROGRESSION IN PT1 HIGH-GRADE UROTHELIAL CARCINOMA OF THE BLADDER / Maria Rosaria Raspollini; Tommaso Jaeger; Tommaso Chini; Ilaria Montagnani; Simone Caroassai; Arcangelo Sebastianelli; Meri Luka; Andrea Chindemi; Daniele Vitelli; Jacopo Frizzi; Andrea Minervini; Alberto Lapini; Federico Lanzi; Gianna Baroni. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 34:(2014), pp. 2672-2673.

A PROPOSED SCORE FOR ASSESSING PROGRESSION IN PT1 HIGH-GRADE UROTHELIAL CARCINOMA OF THE BLADDER

MINERVINI, ANDREA;
2014

Abstract

Aim: We tested a selected series of patients with single urothelial high-grade pT1 stage (pT1 HG) or urothelial carcinoma in situ (CIS) with a set of immunohistochemical markers to elaborate a risk score for progression. Patients and Methods: We retrospectively reviewed all first diagnoses of single, <3 cm, urothelial papillary carcinoma pT1 HG or isolated CIS between 2006 and 2009. Galectin-3, CD44, Ecadherin, CD138, p16, survivin, HYAL-1, and topoisomerase- II α were used. A grading score 0 or 1 for each immunohistochemical staining was assigned to obtain a total score for assessing progression. The median “progression score” was selected as cut-off value for statistical analysis. Overall, 23 patients (19 pT1 HG and 4 CIS) were included in the study. Results: After a median follow-up of 21 months (range, 12 to 34 mo), 9 patients (39.1%) showed disease recurrence whereas 4 patients (17.4%) showed tumor progression. Topoisomerase-II α, p16, survivin, galectin-3, and CD138 were significantly associated with progression. Progression score ranged from 0 (best prognosis) to 7 (worst prognosis). Using a score ≥5 as a threshold, specificity was 78.9%, sensitivity 100%, positive predictive value 50%, and negative predictive value 100%. ROC area (a 95% confidence interval, 0.807-1.000; p<0.001). Conclusion: This immunohistochemistry-based progression score using a threshold ≥5, might help the clinician to focus on patients with HG pT1 or extended CIS at high risk for disease progression. These patients might benefit from a more intensive follow-up program or early cystectomy.
2014
Maria Rosaria Raspollini; Tommaso Jaeger; Tommaso Chini; Ilaria Montagnani; Simone Caroassai; Arcangelo Sebastianelli; Meri Luka; Andrea Chindemi; Daniele Vitelli; Jacopo Frizzi; Andrea Minervini; Alberto Lapini; Federico Lanzi; Gianna Baroni
File in questo prodotto:
File Dimensione Formato  
111.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 61.15 kB
Formato Adobe PDF
61.15 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1056697
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact